Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 159

1.

Evaluation of Distance Metrics and Spatial Autocorrelation in Uniform Manifold Approximation and Projection Applied to Mass Spectrometry Imaging Data.

Smets T, Verbeeck N, Claesen M, Asperger A, Griffioen G, Tousseyn T, Waelput W, Waelkens E, De Moor B.

Anal Chem. 2019 May 7;91(9):5706-5714. doi: 10.1021/acs.analchem.8b05827. Epub 2019 Apr 25.

PMID:
30986042
2.

Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial.

Palma DA, Olson R, Harrow S, Gaede S, Louie AV, Haasbeek C, Mulroy L, Lock M, Rodrigues GB, Yaremko BP, Schellenberg D, Ahmad B, Griffioen G, Senthi S, Swaminath A, Kopek N, Liu M, Moore K, Currie S, Bauman GS, Warner A, Senan S.

Lancet. 2019 May 18;393(10185):2051-2058. doi: 10.1016/S0140-6736(18)32487-5. Epub 2019 Apr 11.

PMID:
30982687
3.

Serotonin 5-HT1A receptor binding and self-transcendence in healthy control subjects-a replication study using Bayesian hypothesis testing.

Griffioen G, Matheson GJ, Cervenka S, Farde L, Borg J.

PeerJ. 2018 Nov 16;6:e5790. doi: 10.7717/peerj.5790. eCollection 2018.

4.

Modifying Rap1-signalling by targeting Pde6δ is neuroprotective in models of Alzheimer's disease.

Dumbacher M, Van Dooren T, Princen K, De Witte K, Farinelli M, Lievens S, Tavernier J, Dehaen W, Wera S, Winderickx J, Allasia S, Kilonda A, Spieser S, Marchand A, Chaltin P, Hoogenraad CC, Griffioen G.

Mol Neurodegener. 2018 Sep 26;13(1):50. doi: 10.1186/s13024-018-0283-3.

5.

High-dose conventional thoracic re-irradiation for lung cancer: updated results.

Tetar S, Dahele M, Griffioen G, Slotman B, Senan S.

Lung Cancer. 2015 May;88(2):235-6. doi: 10.1016/j.lungcan.2015.02.008. Epub 2015 Feb 18. No abstract available.

PMID:
25736570
6.

Second primary lung cancers following a diagnosis of primary head and neck cancer.

Griffioen GH, Louie AV, de Bree R, Smit EF, Paul MA, Slotman BJ, Leemans CR, Senan S.

Lung Cancer. 2015 Apr;88(1):94-9. doi: 10.1016/j.lungcan.2015.01.011. Epub 2015 Jan 23.

PMID:
25662386
7.

Derailed intraneuronal signalling drives pathogenesis in sporadic and familial Alzheimer's disease.

Van Dooren T, Princen K, De Witte K, Griffioen G.

Biomed Res Int. 2014;2014:167024. doi: 10.1155/2014/167024. Epub 2014 Aug 27. Review.

8.

A brief report on outcomes of stereotactic ablative radiotherapy for a second primary lung cancer: evidence in support of routine CT surveillance.

Griffioen GH, Lagerwaard FJ, Haasbeek CJ, Slotman BJ, Senan S.

J Thorac Oncol. 2014 Aug;9(8):1222-5. doi: 10.1097/JTO.0000000000000218.

9.

Technical note: Evaluation of an ear-attached movement sensor to record cow feeding behavior and activity.

Bikker JP, van Laar H, Rump P, Doorenbos J, van Meurs K, Griffioen GM, Dijkstra J.

J Dairy Sci. 2014 May;97(5):2974-9. doi: 10.3168/jds.2013-7560. Epub 2014 Mar 13.

10.

High-dose, conventionally fractionated thoracic reirradiation for lung tumors.

Griffioen GH, Dahele M, de Haan PF, van de Ven PM, Slotman BJ, Senan S.

Lung Cancer. 2014 Mar;83(3):356-62. doi: 10.1016/j.lungcan.2013.12.006. Epub 2013 Dec 24.

PMID:
24433824
11.

Radical treatment of synchronous oligometastatic non-small cell lung carcinoma (NSCLC): patient outcomes and prognostic factors.

Griffioen GH, Toguri D, Dahele M, Warner A, de Haan PF, Rodrigues GB, Slotman BJ, Yaremko BP, Senan S, Palma DA.

Lung Cancer. 2013 Oct;82(1):95-102. doi: 10.1016/j.lungcan.2013.07.023. Epub 2013 Aug 6.

PMID:
23973202
12.

Treatment of multiple primary lung cancers using stereotactic radiotherapy, either with or without surgery.

Griffioen GH, Lagerwaard FJ, Haasbeek CJ, Smit EF, Slotman BJ, Senan S.

Radiother Oncol. 2013 Jun;107(3):403-8. doi: 10.1016/j.radonc.2013.04.026. Epub 2013 Jun 6.

PMID:
23746675
13.

Comparing rigid and deformable dose registration for high dose thoracic re-irradiation.

Senthi S, Griffioen GH, van Sörnsen de Koste JR, Slotman BJ, Senan S.

Radiother Oncol. 2013 Mar;106(3):323-6. doi: 10.1016/j.radonc.2013.01.018. Epub 2013 Feb 27.

PMID:
23453542
14.

Bowel-sparing intensity-modulated radiotherapy (IMRT) for palliation of large-volume pelvic bone metastases: rationale, technique and clinical implementation.

Griffioen G, Dahele M, Jeulink M, Senan S, Slotman B, Verbakel WF.

Acta Oncol. 2013 May;52(4):877-80. doi: 10.3109/0284186X.2012.725943. Epub 2012 Oct 12. No abstract available.

PMID:
23057486
15.

Stereotactic ablative radiotherapy for comprehensive treatment of oligometastatic tumors (SABR-COMET): study protocol for a randomized phase II trial.

Palma DA, Haasbeek CJ, Rodrigues GB, Dahele M, Lock M, Yaremko B, Olson R, Liu M, Panarotto J, Griffioen GH, Gaede S, Slotman B, Senan S.

BMC Cancer. 2012 Jul 23;12:305. doi: 10.1186/1471-2407-12-305.

16.

Anti tumour necrosis factor as risk factor for free perforations in Crohn's disease? A case-control study.

Eshuis EJ, Griffioen GH, Stokkers PC, Ubbink DT, Bemelman WA.

Colorectal Dis. 2012 May;14(5):578-84. doi: 10.1111/j.1463-1318.2011.02764.x.

PMID:
21848898
17.

Substituted 2-aminothiazoles are exceptional inhibitors of neuronal degeneration in tau-driven models of Alzheimer's disease.

Lagoja I, Pannecouque C, Griffioen G, Wera S, Rojasdelaparra VM, Van Aerschot A.

Eur J Pharm Sci. 2011 Aug 17;43(5):386-92. doi: 10.1016/j.ejps.2011.05.014. Epub 2011 Jun 2.

PMID:
21664968
18.

Pathological Hallmarks, Clinical Parallels, and Value for Drug Testing in Alzheimer's Disease of the APP[V717I] London Transgenic Mouse Model.

Tanghe A, Termont A, Merchiers P, Schilling S, Demuth HU, Scrocchi L, Van Leuven F, Griffioen G, Van Dooren T.

Int J Alzheimers Dis. 2010 Sep 2;2010. pii: 417314. doi: 10.4061/2010/417314.

19.

Evaluation of the Vitotox and RadarScreen assays for the rapid assessment of genotoxicity in the early research phase of drug development.

Westerink WM, Stevenson JC, Lauwers A, Griffioen G, Horbach GJ, Schoonen WG.

Mutat Res. 2009 May 31;676(1-2):113-30. doi: 10.1016/j.mrgentox.2009.04.008. Epub 2009 Apr 22.

PMID:
19393335
20.

Clinical evidence for a protective role of lipocalin-2 against MMP-9 autodegradation and the impact for gastric cancer.

Kubben FJ, Sier CF, Hawinkels LJ, Tschesche H, van Duijn W, Zuidwijk K, van der Reijden JJ, Hanemaaijer R, Griffioen G, Lamers CB, Verspaget HW.

Eur J Cancer. 2007 Aug;43(12):1869-76. Epub 2007 Jul 2.

PMID:
17604154
21.
22.

Genotype-phenotype correlations as a guide in the management of familial adenomatous polyposis.

Nieuwenhuis MH, Mathus-Vliegen LM, Slors FJ, Griffioen G, Nagengast FM, Schouten WR, Kleibeuker JH, Vasen HF.

Clin Gastroenterol Hepatol. 2007 Mar;5(3):374-8.

PMID:
17368237
23.

Clinical impact of MMP and TIMP gene polymorphisms in gastric cancer.

Kubben FJ, Sier CF, Meijer MJ, van den Berg M, van der Reijden JJ, Griffioen G, van de Velde CJ, Lamers CB, Verspaget HW.

Br J Cancer. 2006 Sep 18;95(6):744-51. Epub 2006 Aug 29.

24.

What is the appropriate screening protocol in Lynch syndrome?

de Jong AE, Nagengast FM, Kleibeuker JH, van de Meeberg PC, van Wijk HJ, Cats A, Griffioen G, Vasen HF.

Fam Cancer. 2006;5(4):373-8. Epub 2006 Jul 7.

PMID:
16826316
25.

Matrix metalloproteinase-2 is a consistent prognostic factor in gastric cancer.

Kubben FJ, Sier CF, van Duijn W, Griffioen G, Hanemaaijer R, van de Velde CJ, van Krieken JH, Lamers CB, Verspaget HW.

Br J Cancer. 2006 Apr 10;94(7):1035-40.

26.

Decrease in mortality in Lynch syndrome families because of surveillance.

de Jong AE, Hendriks YM, Kleibeuker JH, de Boer SY, Cats A, Griffioen G, Nagengast FM, Nelis FG, Rookus MA, Vasen HF.

Gastroenterology. 2006 Mar;130(3):665-71.

PMID:
16530507
27.

A yeast-based model of alpha-synucleinopathy identifies compounds with therapeutic potential.

Griffioen G, Duhamel H, Van Damme N, Pellens K, Zabrocki P, Pannecouque C, van Leuven F, Winderickx J, Wera S.

Biochim Biophys Acta. 2006 Mar;1762(3):312-8. Epub 2005 Dec 27.

28.

Ileum resection is the most predictive factor for osteoporosis in patients with Crohn's disease.

van Hogezand RA, Bänffer D, Zwinderman AH, McCloskey EV, Griffioen G, Hamdy NA.

Osteoporos Int. 2006;17(4):535-42. Epub 2006 Jan 4.

PMID:
16392028
29.

Characterization of alpha-synuclein aggregation and synergistic toxicity with protein tau in yeast.

Zabrocki P, Pellens K, Vanhelmont T, Vandebroek T, Griffioen G, Wera S, Van Leuven F, Winderickx J.

FEBS J. 2005 Mar;272(6):1386-400.

30.

Endoscopic treatment of Barrett's oesophagus.

Veenendaal RA, Griffioen G, Lamers CB.

Scand J Gastroenterol Suppl. 2004;(241):32-7. Review.

PMID:
15696847
31.

PKA and Sch9 control a molecular switch important for the proper adaptation to nutrient availability.

Roosen J, Engelen K, Marchal K, Mathys J, Griffioen G, Cameroni E, Thevelein JM, De Virgilio C, De Moor B, Winderickx J.

Mol Microbiol. 2005 Feb;55(3):862-80.

32.

Prevalence of adenomas among young individuals at average risk for colorectal cancer.

de Jong AE, Morreau H, Nagengast FM, Mathus-Vliegen EM, Kleibeuker JH, Griffioen G, Cats A, Vasen HF.

Am J Gastroenterol. 2005 Jan;100(1):139-43.

PMID:
15654793
33.

Extending the p16-Leiden tumour spectrum by respiratory tract tumours.

Oldenburg RA, de Vos tot Nederveen Cappel WH, van Puijenbroek M, van den Ouweland A, Bakker E, Griffioen G, Devilee P, Cornelisse CJ, Meijers-Heijboer H, Vasen HF, Morreau H.

J Med Genet. 2004 Mar;41(3):e31. No abstract available.

34.

Survival after adjuvant 5-FU treatment for stage III colon cancer in hereditary nonpolyposis colorectal cancer.

de Vos tot Nederveen Cappel WH, Meulenbeld HJ, Kleibeuker JH, Nagengast FM, Menko FH, Griffioen G, Cats A, Morreau H, Gelderblom H, Vasen HF.

Int J Cancer. 2004 Apr 10;109(3):468-71.

35.

The role of mismatch repair gene defects in the development of adenomas in patients with HNPCC.

De Jong AE, Morreau H, Van Puijenbroek M, Eilers PH, Wijnen J, Nagengast FM, Griffioen G, Cats A, Menko FH, Kleibeuker JH, Vasen HF.

Gastroenterology. 2004 Jan;126(1):42-8.

PMID:
14699485
36.

Decision analysis in the surgical treatment of colorectal cancer due to a mismatch repair gene defect.

de Vos tot Nederveen Cappel WH, Buskens E, van Duijvendijk P, Cats A, Menko FH, Griffioen G, Slors JF, Nagengast FM, Kleibeuker JH, Vasen HF.

Gut. 2003 Dec;52(12):1752-5.

37.

Pancreatic carcinoma in carriers of a specific 19 base pair deletion of CDKN2A/p16 (p16-leiden).

de vos tot Nederveen Cappel WH, Offerhaus GJ, van Puijenbroek M, Caspers E, Gruis NA, De Snoo FA, Lamers CB, Griffioen G, Bergman W, Vasen HF, Morreau H.

Clin Cancer Res. 2003 Sep 1;9(10 Pt 1):3598-605.

38.

Worldwide survey among polyposis registries of surgical management of severe duodenal adenomatosis in familial adenomatous polyposis.

de Vos tot Nederveen Cappel WH, Järvinen HJ, Björk J, Berk T, Griffioen G, Vasen HF.

Br J Surg. 2003 Jun;90(6):705-10.

PMID:
12808618
39.
40.

Surveillance for hereditary nonpolyposis colorectal cancer: a long-term study on 114 families.

de Vos tot Nederveen Cappel WH, Nagengast FM, Griffioen G, Menko FH, Taal BG, Kleibeuker JH, Vasen HF.

Dis Colon Rectum. 2002 Dec;45(12):1588-94.

PMID:
12473880
41.

Molecular mechanisms controlling the localisation of protein kinase A.

Griffioen G, Thevelein JM.

Curr Genet. 2002 Jul;41(4):199-207. Epub 2002 Jun 27. Review.

PMID:
12172960
42.

[Desmoid tumors in patients with familial adenomatous polyposis].

Pikaar A, Nortier JW, Griffioen G, Vasen HF.

Ned Tijdschr Geneeskd. 2002 Jul 20;146(29):1355-9. Review. Dutch.

PMID:
12162172
43.

Prognostic significance of metallothionein in human gastrointestinal cancer.

Janssen AM, van Duijn W, Kubben FJ, Griffioen G, Lamers CB, van Krieken JH, van de Velde CJ, Verspaget HW.

Clin Cancer Res. 2002 Jun;8(6):1889-96.

44.

Ileoanal pouch function is related to postprandial pouch tone.

Steens J, Bemelman WA, Meijerink WJ, Griffioen G, van Hogezand RA, Masclee AA.

Br J Surg. 2001 Nov;88(11):1492-7.

PMID:
11683747
45.

MSH2 mutation carriers are at higher risk of cancer than MLH1 mutation carriers: a study of hereditary nonpolyposis colorectal cancer families.

Vasen HF, Stormorken A, Menko FH, Nagengast FM, Kleibeuker JH, Griffioen G, Taal BG, Moller P, Wijnen JT.

J Clin Oncol. 2001 Oct 15;19(20):4074-80.

PMID:
11600610
46.

Barium enema and endoscopy for the detection of colorectal neoplasia: sensitivity, specificity, complications and its determinants.

de Zwart IM, Griffioen G, Shaw MP, Lamers CB, de Roos A.

Clin Radiol. 2001 May;56(5):401-9. Review.

PMID:
11384140
47.

Comparison of ileoanal pouch and rectal function measured by barostat.

Steens J, Penning C, Bemelman WA, Griffioen G, Van Hogezand RA, Meijerink WJ, Lamers CB, Masclee AA.

Dig Dis Sci. 2001 Apr;46(4):731-8.

PMID:
11330405
48.

How effective is extensive nonsurgical treatment of patients with clinically active Crohn's disease of the terminal ileum in preventing surgery?

Bemelman WA, Ivenski M, van Hogezand RA, Hermans J, Veenendaal RA, Griffioen G.

Dig Surg. 2001;18(1):56-60.

PMID:
11244261
49.

Chemoprevention of colorectal cancer by non-steroidal anti-inflammatory drugs.

Bus PJ, Verspaget HW, Lamers CB, Griffioen G.

Scand J Gastroenterol Suppl. 2000;(232):101-4. Review.

PMID:
11232485
50.

Supplemental Content

Loading ...
Support Center